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Abstract  
The Gram-negative anaerobe Porphyromonas gingivalis is associated with chronic 
periodontitis. Clinical isolates of P. gingivalis strains with high dipeptidyl peptidase 4 (DPP4) 
expression also had a high capacity for biofilm formation and were more infective. The X-ray 
crystal structure of P. gingivalis DPP4 was solved at 2.2 Å resolution. Despite a sequence 
identity of 32%, the overall structure of the dimer was conserved between P. gingivalis DPP4 
and mammalian orthologs. The structures of the substrate binding sites were also conserved, 
except for the region called S2-extensive, which is exploited by specific human DPP4 
inhibitors currently used as antidiabetic drugs. Screening of a collection of 450 compounds as 
inhibitors revealed a structure-activity relationship that mimics in part that of mammalian 
DPP9. The functional similarity between human and bacterial DPP4 was confirmed using 124 
potential peptide substrates. 
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1. Introduction  
Periodontal disease develops when bacteria of the dental plaque migrate from the dental 
root hard tissues to nearby soft tissues. This results in chronic inflammation leading to 
destruction of the periodontal ligament and the alveolar bone that supports the teeth. The 
process by which a generally benign biofilm transforms into pathological periodontitis is 
complex and remains poorly understood. However, the presence of one particular species, the 
Gram-negative anaerobe Porphyromonas gingivalis, is considered to be an indicator of 
progression of chronic periodontitis[1, 2]. Periodontal disease, and specifically the presence 
of P. gingivalis, are risk factors for cardiovascular disease, aspiration pneumonia and low 
birth weight [3-5]. A wide array of virulence factors have been described for P. gingivalis that 
reflect the different processes by which the bacterium transforms from a commensal organism 
to a pathogen: biofilm formation, anaerobic growth, adhesion, suppression/activation of 
inflammatory responses, invasion, tissue degradation and intracellular survival in gingival 
epithelial cells and host immune cells (reviewed by [6, 7]). P. gingivalis produces a unique set 
of proteases that are believed to be required for nutrient provision during its compulsory 
asaccharolytic growth, but may also contribute to evasion of the host immune system, 
adhesion and degradation of extracellular matrix[8-10]. One of these proteases is P. gingivalis 
dipeptidyl peptidase 4 (pgDPP4). The gene encoding pgDPP4 was first sequenced and cloned 
in 2000 [11], and the protein is secreted but remains associated with the membrane [12]. 
PgDPP4 is a proline-specific dipeptidyl peptidase that cleaves peptides related to immune 
responses and inflammation in vitro. Evidence suggests pgDPP4 interacts with extracellular 
matrix proteins such as fibronectin and collagen, thereby promoting collagen degradation by 
matrix metalloproteinases activated by the host inflammatory response [13, 14]. Mice injected 
with a DPP4-deficient mutant strain developed less abscesses and survived longer than mice 
injected with the wild type (W83) strain [11], implicating pgDPP4 as a virulence factor. 
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Transfection with recombinant pgDPP4 restored virulence, while a catalytically impaired 
DPP4 only partially restored the wild type phenotype [15]. Moreover, clinical isolates of P. 
gingivalis strains with high DPP4 expression had a higher capacity for biofilm formation and 
were more infective in a mouse abscess model [16]. 
pgDPP4 belongs to the same family of proteases (prolyl oligopeptidase family, S9 clanB, 
MEROPS database) as human DPP4 (hDPP4), with which it shares 32% amino acid sequence 
identity. This indicates a similar topology and enzymatic mechanism. Even though the 
catalytic residues and side chains forming the primary substrate-binding site are conserved, 
we noticed significant differences in the potency of selected inhibitors, and in the substrate 
specificity, between the bacterial and human enzymes [17]. Following preliminary 
crystallization experiments [18], one of the aims of the present study was to identify the 
origins of these differences in the structure of pgDPP4, as a prerequisite to developing more 
specific inhibitors in the future. Both enzymes likely share substrates present in the oral 
cavity, the gingival epithelium and sites of inflammation.  
In humans, the inhibition of DPP4 catalyzed inactivation of incretins (intestinal peptides 
regulating insulin secretion) proved to be successful for the treatment of type 2 diabetes [19]. 
Over the last two decades, numerous DPP4 inhibitors have been synthesized, screened and 
tested for their antidiabetic activity, while other compounds have been prepared to address 
selectivity and to investigate the roles of several related peptidases. Thus, there exists a 
sizable collection of mammalian DPP family inhibitors available for screening against other 
targets. The collection used in the present work includes compounds that have been developed 
and characterized at the University of Antwerp during a longstanding research program on 
various peptidases, including DPP4, DPP2, DPP8, DPP9, fibroblast activating protein-α 
(FAP) and prolyl oligopeptidase (PREP). They are based on several chemical scaffolds [20-
33]. The collection also includes reference compounds, such as the antidiabetic drugs 
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sitagliptin, vildagliptin and linagliptin, and prototypical DPP2, DPP8/9 and FAP inhibitors. 
The aim of this study was to screen the collection of compounds present at the University of 
Antwerp. Additionally, an assortment of secreted peptides present at the University of Leuven 
was used as a substrate collection in order to investigate structure-function relationships in the 
active site of pgDPP4. 
 
2. Results 
2.1. Structural alignment of pgDPP4 and hDPP4 
The overall structural similarity between both DPP4s is shown in Figure 1. A sequence 
alignment with species-specific numbering is shown in the supplementary material.  
Figure 2 depicts the catalytic residues of pgDPP4 positioned in the electron density map. 
The active sites of pgDPP4 and hDPP4 are evidently similar. Direct transfer of the 
coordinates of the hDPP4 structures with different ligands into the active site of the aligned 
pgDPP4 structure (i.e. docking of ligands in pgDPP4 active site) reveals similar substrate 
binding pockets for both DPP4 enzymes. Table S1 in the supplementary material provides a 
list of all hDPP4 structures used in this work, together with references to the Protein Structure 
Database (PDB) and the original publications. 
A narrow but deep S1-pocket is located next to the catalytic Ser-593 (adopting pgDPP4 
numbering), and direct mapping of the many co-crystallized ligands from the human 
structures into the pgDPP4 structure reveals that this pocket could potentially accommodate a 
proline-moiety like the pyrrolidine ring of the Val-pyrrolidide or a phenyl or halogen-
substituted phenyl of many other ligands, including vildagliptin and sitagliptin (Table S1). 
The residues flanking the S1-pocket are identical in the human and P. gingivalis enzymes. 
The S1-pocket is hydrophobic; lipophilic residues Tyr-594, Tyr-625, Tyr-629, Trp-622 and 
Val-619 are located within 4 Å of the pyrrolidine ring of the co-crystallized Val-pyrrolidide 
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ligand from the human structure (PDB ID A3M) A visual representation of the S1 pocket can 
be found in Figure 4 of the paper by Rasmussen et al., 2002 [34]. 
In both DPP4 enzymes, the positive charge of the amino terminus of the substrate peptide 
is neutralized by the negative charges from two glutamate residues flanking the S2-pocket, 
namely Glu-195 and Glu-196. The location of both residues is identical in the two enzymes. 
Almost all analyzed ligands from the human DPP4 crystals contain a functionality that 
mimics the interaction with the two S2-flanking glutamates through a primary or secondary 
amine. The only exception is the diisopropyl fluorophosphate ligand (DFP) from the 1TKR 
crystal structure, since this ligand does not occupy the S2-pocket at all. Also noteworthy is the 
binding mode of compound 5AP (Pdb: 1RWQ, Table S1), since in addition to the normal 
interaction of the glutamates with the benzylamino group of 5AP, an additional hydrogen 
bond is formed between the aniline on the pyrimidine moiety and the backbone carbonyl of 
Glu-195. 
Many of the co-crystallized ligands in hDPP4 bind well beyond the S2-pocket in a subsite 
labeled as “S2-extensive”. According to structural analysis performed by Nabeno and 
coworkers, this pocket is not defined in other related proline specific peptidases such as 
DPP8, DPP9 and fibroblast activating protein-α [35]. In hDPP4, the S2-extensive pocket is 
flanked by residues Val-207, Ser-209, Phe-357 and Arg-358 (hDPP4 numbering). Based on 
the structural alignment, these residues are not completely conserved in pgDPP4. Val-207 
corresponds to Phe-197 in pgDPP4, the human Ser-209 corresponds to Gly-198 of pgDPP4 
(with a deletion of the human Phe-208 for which there is no matching alternative in pgDPP4), 
Arg-358 corresponds to Asp-329 in pgDPP4, and the human Phe-357 has no immediate 
equivalent in pgDPP4 which makes the human S2-extensive pocket somewhat smaller 
(Figure 3). 
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The amino acid differences between the human and P. gingivalis S2-extensive pocket 
might have implications for the design of selective drugs. It could be argued that ligands that 
take advantage of these local differences of the S2-extensive pocket might be more selective 
against a particular DPP4 form. A number of hDPP4 inhibitors have been described that form 
interactions with Phe-357 and Arg-358 of the human enzyme. These residues are located 
along the same side of the pocket. For example, compound S14 (Pdb: 2FJP) forms a hydrogen 
bond with Arg-358 and also forms a stacking interaction with the phenyl ring of Phe-357. 
Additionally, both sitagliptin and teneligliptin undergo stacking interactions with the 
sidechain of Phe-357 (Figure 3). 
On the other side of the S2-extensive pocket, where Val-207 and Ser-209 are located in 
the human form, there are less opportunities for the design of more selective inhibitors since 
none of the co-crystallized examples in hDPP4 interact with either of these two residues. 
2.2. Screening of the inhibitor collection 
A collection of 450 compounds was screened, including clinically used DPP4 inhibitors 
and some reference compounds, shown in Scheme 1 and Table 1. Most of the compounds 
were dipeptide derivatives. Of these 81 exhibited more than 50% inhibition at a concentration 
of 100 µM, and 33 displayed greater than 50% inhibition at 10 µM. As a rule, IC50 values 
were only determined for compounds that gave more than 50% inhibition at 10 µM. For the 
latter compounds IC50 values ranged between 10 and 0.05 µM (supplementary material, 
Table S2). Compounds with a protected amino terminus, targetting PREP and FAP [22, 23, 
25, 30], showed no inhibition, confirming that pgDPP4 is a true dipeptidyl peptidase. 
Compounds with an isoindoline derivative in the P1 position (which confers selectivity 
towards DPP8/9)[33] in general did not appreciably inhibit pgDPP4, and neither did 
compounds with a phosphonate moiety attached to P1 (irreversible DPP inhibitors)[31]. The 
remaining compounds were assigned to two classes, based on their structural scaffold. Class 1 
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contains compounds with a variation of amino acids in P2 in combination with pyrrolidine or 
variations thereon in P1. Class 2 compounds have a variation in P2, not limited to natural 
amino acids, and have combinations of substitutions on the pyrrolidine ring. 
2.3. Structure-activity relationships (SAR) of inhibitors: S1 and S2 binding sites 
Class 1 contains compounds that are based on Xaa-pyrrolidide, where Xaa is a variety of 
amino acids; and compounds that contain variable motifs replacing the pyrrole ring with Xaa 
= Ile, allo-Ile, Lys, Z-Lys or cyclohexylalanine. A preliminary study already demonstrated 
differences between pgDPP4 and human DPP4 [17], and the results of this small-scale study 
were reproduced and extended in the present work. Inhibition of pgDPP4 by Xaa-pyrrolidides 
was ordered: Val ≈ Ile ≈ allo-Ile ≈ Lys ≈ Z-Lys ≈ Thr, Z-Orn, Arg, ZZ-Arg, norleu > Pro > 
Tyr > Ala > Cha, Phe, Trp, Cys, Orn, Glu, Gly. This is similar to hDPP4, except for lysine 
and threonine, which are more preferred by pgDPP4. By comparison, allo-Ile, Z-Lys and Lys 
are present in P2 position of the strongest inhibitors of DPP9, and ZZ-Arg, His, Arg, Z-Orn, 
Z-lys, Orn and Lys pyrrolidides are all very good inhibitors for DPP2. Although Thr is not the 
best P2 residue for pgDPP4, it is the most effective for separating it from hDPP4, DPP9 and 
DPP2. The IC50 of Tyr-pyrrolidide was between 10 and 100 µM. Notably, a P2 proline is 
accepted less well by pgDPP4 than by hDPP4.   
Still in class 1, it was found that at the P1 position the five-membered pyrrolidide ring is 
optimal for both DPP4s but the slightly larger piperidine provides some selectivity for 
pgDPP4. Ile-4-hydroxy-pyrrolidide was present in the inhibitor library but its affinity for 
pgDPP4 (and hDPP4) is at least 10-fold lower than Ile-pyrrolidide. Larger structures in P1 
lead to loss of affinity. Isoindoline, which conveys selectivity for DPP8/9, generally gives 
poor inhibition of pgDPP4. Substituents on the pyrrolidide ring increase the affinity for the 
pgDPP4 active site. It has been known for some time that electrophiles such as a nitrile group 
on C2 can ameliorate the IC50 for all DPPs [29]. This is also the case for pgDPP4. The 
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combination of an azide group at position 3 improves binding to pgDPP4 more than to 
hDPP4, but the resulting compounds still have a low selectivity. 
Class 2 includes 2-cyano,4-azido-pyrrolidides with isoleucine, allo-isoleucine, lysine and 
glutamate or aspartate derivatives at the P2 position. In this class, the most selective pgDPP4 
inhibitors were Lys-3-azo-2-cyano-pyrrolidide and N-2-naphtyl-Lys-4-azo-2-cyano-
pyrrolidide, which were seven-fold more active against pgDPP4 than hDPP4. Large 
substituents on the lysine side chain appear to be easily accommodated, a property shared 
with human DPP2 and DPP8/9. When polar groups are introduced in the P2 side chain in a 
series of substituted Asp or Glu derivatives, there is a strict selectivity for a two-carbon spacer 
between the Cα and the carbonyl carbon atom. The resulting SAR is given in Table 2, and 
Figure 4 displays the selectivity of the most potent compounds towards hDPP4 and DPP9. By 
analogy with hDPP4, one assumes that the compounds lacking the carbonitrile warhead are 
fast, reversible inhibitors. The kinetics of binding of vildagliptin and compounds 16, 17 and 
18 were monitored, but in all cases maximal inhibition was observed immediately after 
mixing and remained constant for 1 hour. 
2.4. Structure-activity relationship in the S’ substrate binding sites 
Most of the compounds screened vary in the P1 and P2 positions. Interactions with the S’ 
substrate binding sites were not considered. There is one structure of hDPP4 (Pdb: 1NU8) that 
contains the inhibitor/substrate Ile-Pro-Ile. In this structure the C-terminal isoleucine side 
chain is accommodated in the S1’ site. Reasoning that the extended substrate recognition site 
may reach further than the S1’ site, we investigated the substrate specificity of pgDPP and 
hDPP with a collection of 123 peptides (4 to 25 amino acids long) containing an N-terminal 
Xaa-Pro/Ala/Ser/Gly sequence (in almost equal proportion). In the conditions tested, 23 of 
these were cleaved by hDPP4 and 32 were hydrolyzed by pgDPP4. Pro and Ala on the P1 
position determine the substrate specificity. None of the Xaa-Ser-containing peptides were 
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cleaved, and only one Xaa-Gly peptide was processed. Peptides with a Xaa-Pro-Pro or Xaa-
Ala-Pro motif were not cleaved either. The observed differences in the number of peptides 
cleaved, along with the frequency plots, indicate subtle differences between the DPP4s. 
pgDPP4 cleaved peptides have a higher frequency of aliphatic/hydrophobic side chains (V, F, 
L) in the P1’ position than the average peptide in the collection. Eleven peptides were cleaved 
by pgDPP4 but not by the human counterpart. Of these, five peptides had a penultimate 
proline and six contained one or two prolines in the P2’ to P4’ region. The P2-P2’ sequences 
of the peptides cleaved by pgDPP4 were used to construct a selectivity matrix (Table 3). 
 
3. Discussion  
The new crystal structure of pgDPP4 provides experimental evidence that, despite the low 
sequence identity, this bacterial enzyme has the same overall structure and catalytic 
mechanism as the human homolog. All key features of the catalytic machinery are structurally 
conserved, including the S1 pocket accommodating the proline, the catalytic triad, the oxy-
anion hole required for stabilisation of the transition state and tetrahedral intermediates, the 
two glutamates that bind the positively charged N-terminus of the substrate and the S1’ 
pocket that maintains a sharp bend in the substrate’s backbone. All these features have been 
described in the hDPP4 literature [34-36]. This structural conservation is also reflected in the 
fact that, with a few exceptions, both enzymes cleave the same substrates in a biologically 
relevant peptide collection (Table 3). However, there are local differences in areas that are not 
within reach of the side chains of the natural substrates but are occupied by synthetic 
inhibitors of hDPP4, notably the S2-extensive pocket (Figure 3). Even though it was not 
possible to obtain ligand-bound structures in the specific crystallisation conditions, the 
pgDPP4 structure proved instrumental in understanding the specificty of inhibitors and may 
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be usefull in future drug development projects targetting other proline specific dipeptidyl 
peptidases. 
The conservation of the catalytic machinery provides an explanation for the increase in 
potency when a reactive group, a “warhead”, is present on the P1 of the inhibitors. In Table 2 
and Figure 4, one observes a 10-fold increase in potency when a carbonitrile group is placed 
on the C2 of the pyrrolidide ring. The nitrile group is considered to sit in the active site as a 
transition state analog where the oxyanion hole provides stabilisation of a negative charge on 
the nitrogen, thus activating the carbon atom for a nucleophilic attack by the active site serine. 
This significantly enhances binding compared to compounds that lack the warhead and are 
otherwise the same. For hDPP4 and PREP, this has been observed on numerous occasions 
since the first reports in the 1990’s [37]. This type of inhitor is often called covalent, because 
in the crystal structures there is a short contact between the carbonitrile carbon atom and the 
oxygen of the site chain of the catalytic serine. From enzyme kinetics one cannot deduce 
whether these compounds form a covalent bond, since they behave as reversible competitive 
inhibitors. Very potent compounds sometimes display slow-binding and hyperbolic kinetics 
[38, 39]. However, since the pgDPP4 structure has no ligand and inhibition was essentially 
instantaneous, it remains unknown whether a covalent interaction occurs between the catalytic 
serine and the carbonitrile containing compounds of this study. Assuming that all the 
compounds are reversible competitive inhibitors, and considering that the IC50 values were 
determined at a substrate concentration equal to the Km, the IC50 values are a measure of the 
inhibition constants (Ki), allowing direct comparison of the potency between the different 
enzymes. 
The pgDPP4 pharmacophore that emerged from the screening is shown in Figure 5. In P1 
a pyrrolidine is preferred, but in combination with certain P2 components, isoindoline and 
pyridine are accepted (for example 43, 83, 84 and 64 in Table S2)[17]. This is not the case for 
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hDPP4 so it may be concluded that the S1 pocket of pgDPP4 is slightly larger than that of 
hDPP4, but not as large as that of DPP9 which prefers an isoindoline [33]. The carbonitrile 
warhead improves potency, but this is not specific for pgDPP4 because it is also observed 
with hDPP4, DPP9, DPP8 and DPP2 [29]. It requires (S) stereochemistry, like the peptide 
backbone of the natural substrates. A boronic acid in this position also improves potency (but 
not selectivity, 3 Table 1) and contrary to hDPP4 and DPP8, diphenyl phosphonates are 
ineffective [17, 31], a phenomenon that is difficult to rationalize from the structure. The 
introduction of an azide group on the C4 affords a specific effect that is absent with hDPP4 
but present with DPP9. Consequently, compounds 13 – 17 have a higher potency for pgDPP4 
than for hDPP4 but the selectivity towards DPP9 does not change much. In Figure 4, the line 
representing DPP9 inhibition is more or less parallel with the diagonal, indicating that the 
contribution of the azide substituent is independent from the P2 component. The azide 
substituent has to be in cis relative to the carbonitrile (17 in Table 2 and 46 in Table S2). In 
previous studies inhibitors were optimized for binding to DPP9 [21, 29, 30, 32]. The results of 
the screening show an overlap between the pharmacophores of pgDPP4 and DPP9 with 
respect to the azide and the P2 component. The best P2 residues are large, often with a 
nitrogen atom on a carbon spacer and substituted with bulky or aromatic groups (16, 18 in 
Table 2 and 69, 72, 73 in Table S2). The most likely explanation is that they bind specifically 
in the S2-extensive pocket which is deeper than in hDPP4 and has a different charge 
distribution (Figure 3). Since there is only a homology model but no crystal structure of DPP9 
in the public domain, the results strongly suggest that the S2-extensive binding site could be 
targetted with likely success in DPP9 (and DPP8) [40]. DPP9 inhibitors are currently used to 
investigate a potential role of DPP9 in inflammation but it is too soon to predict a use in 
therapy [41, 42]. 
14 
 
By including the peptide collection, this study addressed the potential of the S’ binding 
sites for selectivity. However, from the crystal structure, there appears little evidence that 
enzyme-substrate interactions occur beyond the S2’ site. The observed differences between 
human and pgDPP4 probably derive from structural properties of proline-containing peptides. 
Knowledge of the catalytic potency of serine proteases relies largely on historical studies with 
chymotrypsin and related proteases. How the different S9 family members deal with the 
intricacies of the chemistry required to cleave a post-proline bond therefore deserves further 
investigation [39]. 
In this study, we compared P. gingivalis DPP4 with human DPP4, and the results may be 
extrapolated to other bacterial DPP4s. The structure of at least one other bacterial DPP4 has 
been studied, namely the homolog from Stenotrophomonas maltophilia, which has the ability 
to hydrolyze peptide bonds following 4-hydroxy-proline, as are found in collagen (PDB ID 
2ECF)[43]. As our knowledge of bacterial genomes is rapidly expanding, it is very likely that 
other bacterial DPP4s will be discovered [44], and it may be interesting to verify whether they 
bind to the compounds currently used as antidiabetics. Although it is not completely clear at 
the moment how bacterial DPPs could be exploited as targets, this work at least offers a 
starting point for the development of specific compounds for bacterial enzymes; or a 
secundary use for existing drugs in the future. 
 
4. Conclusion  
Concluding, hDPP4 and pgDPP4 have very similar overall structure and substrate specificity. 
Nevertheless, screening of the available inhibitor collection and docking of compounds in the 
pgDPP4 active site revealed that the clinically used DPP4 inhibitors have little affinity for 
pgDPP4. On the other hand, there is a certain overlap between the pgDPP4 and DPP9 
pharmacophores. The crystal structure of pgDPP4 provides a starting point for the 
15 
 
optimisation of inhibitors in the future and for an increased understanding of inhibitor 
selectivity for proline specific peptidases in general. 
 
5. Experimental section 
5.1. Materials 
Gly-Pro-p-nitroanilide was purchased from Sigma (Diegem, Belgium). Inhibitor synthesis 
was described in the original publications [20-33]. Synthetic peptides were acquired from 
Thermo Scientific.  
Cloning, expression and purification of recombinant pgDPP4 were performed as 
previously described [18]. 
5.2. Activity and inhibition measurements 
Initial rates were determined by monitoring the release of p-nitroaniline at 405 nm using a 
Versamax (Molecular Devices, Sunnyvale CA, USA) microtiter plate reader at 37°C. The 
molar absorptivity of p-nitroanilide was 10,200 M-1cm-1 and the path length was 0.58 cm. The 
reaction volume was 200 µl and contained ~0.2 mU of pgDPP4 and 0.25 mM Gly-Pro-p-
nitroanilide in 50 mM TRIS-buffer, pH 8.3 containing 5% DMSO. Inhibitor stock solutions 
(100 mM) were made and diluted to 20x the final concentration in DMSO. Inhibitors were 
screened at a final concentration of 100 µM and 10 µM. For inhibitors with more than 50% 
inhibition at 10 µM, IC50 values were determined using 6 - 10 different inhibitor 
concentrations yielding between 90% and 10% inhibition. All measurements were performed 
in duplicate. IC50 values were calculated by fitting the data with the 4-parameter logistics 
equation using Grafit v5. 
Assays for human DPP4 and bovine DPP9 were performed as described previously [29]. 
5.3. Enzyme-catalyzed peptide hydrolysis 
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The University of Leuven collection of putative neuropeptides and endocrine peptides was 
based on a combination of peptidomics results and bioinformatics [45, 46]. Peptides with a 
penultimate proline, alanine, glycine or serine were chosen for this study. Peptides were 
incubated at a final concentration of 15 µM with 50 U/L DPP4 in 50 mM ammonium 
bicarbonate for 1 h at 37°C. The reaction was stopped by addition of 0.1% trifluoroacetic 
acid. The mixture was spotted on a MALDI plate, left to dry and spotted with 5 mg/mL α-
cyano-4-hydroxycinnamic acid matrix (Sigma, Diegem, Belgium) in 0.1%:50% trifluoroacetic 
acid:acetonitrile. Spectra were recorded with a MALDI TOF/TOF analyzer 4800 plus 
(Applied Biosystems, Foster City, CA, USA) in positive reflector mode over a mass range of 
800-3500 or 300-2000 Da, depending on the size of the peptides. 
 
5.4. Crystallization, structure determination, model building and refinement 
Recombinant pgDPP4 was crystallized as previously described [18] using the hanging- 
drop vapour-diffusion technique in 40% 2-methyl-2,4-pentanediol and 100 mM TRIS-HCl pH 
8.0. Despite pgDpp4 sharing only 32% sequence identity with the porcine and human 
enzymes, partial molecular replacement was successful using the structures of these enzymes 
as search models. Diffraction data were therefore collected from selenomethionine-derived 
PgDpp4 crystals for structure determination by Multiwavelength Anomalous Dispersion 
(MAD). Crystals were removed from the crystallization drop using a nylon loop, transferred 
directly to liquid nitrogen, and stored until needed. X-ray diffraction data to a resolution of 
2.7 Å were collected from selenomethionine-derived crystals at peak, inflection point and 
remote wavelengths on beam line ID14-4 at the ESRF, Grenoble, following a fluorescence 
scan. All data were indexed, integrated and scaled with the HKL package [47]. Following 
anomalous Fourier synthesis from the molecular replacement partial solution using PHASER 
[48], the program SOLVE [49] successfully found 21 of the 25 selenium sites present in each 
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of the eight subunits. After automatic model building using RESOLVE [49] and density 
modification with BUCCANEER [50], it was clear that some parts of some subunits were 
largely disordered. We therefore abandoned this attempt at structure solution and pursued a 
different crystal form. New crystallization screens were set up with a fresh batch of protein 
and crystals were successfully grown in condition H10 of the MORPHEUS crystallization 
screen [51] in a solution containing 10% (w/v) PEG 8000, 20% (v/v) ethylene glycol, 0.02 M 
sodium L-glutamate, 0.02 M DL-alanine, 0.02 M glycine, 0.02 M DL-lysine, 0.02 M DL-
serine, and 0.1 M BICINE/TRIS pH 8.5.The new crystal form diffracted X-rays to 2.2Å 
resolution at our in-house X-ray source, and crystals belonged to the tetragonal space group 
P41212 with one molecule (half a dimer) in the crystallographic asymmetric unit. Data were 
processed by XDS [52] and CCP4 [53], and the structure was solved by PHASER [48], which 
is reported here. The resulting model was improved by iterative rounds of refinement and 
model building using REFMAC5 and O [54, 55]. Water molecules were added to the atomic 
model automatically using ARP-w-ARP [56] at the positions of large positive peaks in the 
difference electron density, only at places where the resulting water molecule fell into an 
appropriate hydrogen bonding environment. Data processing and refinement statistics are 
given in Table 4. The final model contains residues 21-723, and was visualized in, and 
figures produced using, PyMol [57]. 
The PDB ID is 5OLJ. 
 
5.5. Modeling and docking 
The crystal structures of many human DPP4 (hDPP4) proteins, co-crystallized with 
substrate analogues or other types of inhibitors, were taken from the PDB. The structures used 
are listed in supplementary material Table S1. The coordinates of the catalytic triad residues 
from each of these human DPP4s were structurally aligned onto the corresponding pgDPP4 
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coordinates and the derived transformation matrices were subsequently applied to each of the 
co-crystallized ligands. 
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Scheme 1 
Table 1: Potency and selectivity of reference compounds. 
Cpd IC50 (µM) ref 
PgDPP4 DPP4 DPP8 DPP9 DPP2  
1 29  1 5.4  0.3 5.2  0.3 11.3  0.48  153  12 [29] 
2 19  2 1.7  0.1 6.0  3.7 6.6  0.4 28  9 [29] 
3 0.14  0.01 0.022  0.001 0.051  0.002 Not reported 0.086  0.007 [58] 
4 1.3  0.2 0.12  0.01* 9.0  0.1 0.68  0.02 > 1000 [35] 
5 18  1 0.04  0.001 > 50 > 100 > 100 [59] 
6 > 100 165  9 142  27 76.6  6.1 < 0.0005 [27] 
7 10 - 100 90  4 0.12  0.01 0.29  0.02 29  1  [60] 
8 10 -100 0.002  0.0002 > 100 > 100 > 100 [61] 
*Vildagliptin (4) is a slow-binding inhibitor with a Ki of 17 nM [38], its potency is 
underestimated by the IC50 value which was determined with a 15 min pre-incubation.  
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Table 2: IC50 values and selectivity of representative inhibitors  
 
Compound Xaa R1 R2 IC50 (µM) S.I.* Ref# 
9 Z-Lys H H 22 ± 3§ 0.7 [29] 
10 Lys CN H 1.6 ± 0.1 0.2 [29] 
11 Z-Lys CN H 1.5 ± 0.1 0.02 [29] 
12 2-amino-ethyl-Glu CN N3 0.8 ± 0.6 0.5 [21] 
13 piperazine-Glu CN N3 0.48 ± 0.04 1.2 [21] 
14 Lys CN N3 0.33 ± 0.01 6.7 [29] 
15 Ile CN N3 0.31 ± 0.03 1.1 [29] 
16 Z-Lys CN N3 0.30 ± 0.02 1.8 [29] 
17 allo-Ile CN N3 0.23 ± 0.01 1.3 [29] 
18 2-naphtyl-Lys CN N3 0.079 ± 0.006 7.1 [29] 
*Selectivity index = IC50 hDPP4 / IC50 pgDPP4. 
§standard error on the fit. #original reference 
for IC50 values with hDPP4. 
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Table 3: Substrate specificity matrix of pgDPP4 
 
Amino acid P2 P1 P1’ P2’ 
Gly 1/5* 1/21 2/8 1/4 
Pro  15/28 0/4 2/7 
Ala 3/5 12/31 2/4 2/4 
Val 2/2  3/5 2/4 
Leu 3/5  3/5 5/6 
Ile 0/1    
Met 3/5   2/3 
Phe 0/1  4/6 1/1 
Tyr 2/2  1/1  
Trp 0/1  1/2  
Ser 3/7 0/25 2/3 3/6 
Thr 0/2  2/4 2/4 
Cys    0/2 
Asn 1/1  3/4 0/2 
Gln 3/4  1/2 1/2 
Asp 3/8  0/1 1/3 
Glu 1/3  1/2 1/4 
Lys 1/4  2/4 1/2 
Arg 0/1  1/3 4/4 
His 2/3  0/2 0/2 
*The frequency of cleavage is given by the ratio i/n with i the number of times the amino acid 
appears at the given position in a cleaved peptide and n the number of times the amino acid is 
present at the given position in the collection (sum of cleaved and uncleaved peptides). Xaa-
Ser containing and Xaa-Gly containing peptides were not included in the specificity matrix 
and logo. Only unique P2-P2’ sequences were considered. Peptides with a blocked N-
terminus were not included. The distribution logo was made by http://weblogo.berkeley.edu. 
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Table 4. Summary of crystallographic data collection and refinement statistics 
 
Data collection  
Radiation, detector and wavelength (Å) CuK MAR345, 1.5418 
Unit cell (Å) a= b=109.10, c= 157.81 
Space group P41212 
Resolution (Å) 38-2.2 (2.32-2.2) 
Observations 453,350 
Unique reflections 48,811 
I/(I) 10.8 (3.3) 
Rsym
a 0.424 (0.971) 
Completeness (%) 
CC1/2
b 
99.7 (96.6) 
0.992 (0.973) 
Refinement  
Non-hydrogen atoms 6,034 (including 1 glycerol & 396 waters) 
Rcryst
c 
Reflections used 
0.224 (0.529) 
46,837 (3,288) 
Rfree
d 
Reflections used 
0.254 (0.531) 
1,974 (137) 
Rcryst (all data)
b 0.225 
Average temperature factors (Å2) 
All atoms 
Protein 
Glycerol 
Water 
 
16.7 
16.6 
31.2 
16.2 
Rmsds from ideal values  
Bonds (Å) 0.014 
Angles (o) 1.6 
DPI coordinate error (Å)e 
Ramachandran Plot (%) 
Most favoured 
Additional allowed 
Outliers 
wwPDB code 
0.18 
 
96.1 
3.6 
0.3 
5OLJ 
Numbers in parentheses refer to values in the highest resolution shell. 
aRsym = jh|Ih,j - <Ih>|/jh<Ih> where Ih,j is the jth observation of reflection h, and <Ih> is the 
mean intensity of that reflection 
bCC1/2 is the correlation coefficient of the mean intensities between two random half-sets of 
data 
cRcryst = ||Fobs|-|Fcalc||/|Fobs| where Fobs and Fcalc are the observed and calculated structure 
factor  amplitudes, respectively 
dRfree is equivalent to Rcryst for a 4% subset of reflections not used in the refinement 
eDPI refers to the diffraction component precision index [62] 
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Figures 
 
Figure 1: overall structural alignment of pgDPP4 and hDPP4 
Superposition of the crystal structures of human (cyan) and P. gingivalis (yellow) DPP4. The 
structure of the human form was taken from Grimshaw and coworkers (PDB ID 5KBY)[63]. 
The both structures are composed of two homodimers that are related by a two-fold axis. The 
catalytic triad residues in both structures are indicated with solid red spheres. Root-mean-
squared deviation between the Cα atoms of both structures is 1.0 Å, indicating an extremely 
high level of structural similarity between the two proteins. 
  
24 
 
 
Figure 2: the active site of pgDPP4 
Ser593, His700 and Asp668 make up the catalytic triad. Tyr511 is part of the oxyanion 
binding site, Tyr625 and Asn670 are part of the non-specific peptide/inhibitor binding sites. 
Important hydrogen bonds are shown as dotted lines. The SIGMAA [64] weighted 2mFo-ΔFc 
electron density is contoured at the 1.0 σ level, where σ represents the RMS electron density 
for the unit cell. Contours more than 1.4 Å from any of the displayed atoms have been 
removed for clarity. 
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Figure 3: the S2 extensive pocket 
(a) Overlay of the structures of pg DPP4 (green, without ligand) and hDPP4 (cyan, with 
ligand), highlighting the differences in the ‘S2-extensive’ pocket. Shown is the adamantyl 
sidechain of saxagliptin (PDB ID 3BJM)[36] and the surface (cyan with positive and negative 
charges in blue and red, respectively) of hDPP4 as composed by residues Val-207, Ser-209, 
Phe-357 and Arg-358 (human numbering). The surface from Arg-358 is encircled in white 
and the surface from Ser-209 is encircled in orange. (b) Same view but now showing the 
surface (green with positive and negative charges in blue and red, respectively) of the 
equivalent area of pgDPP4. The surface from Asp-329 is encircled in white and the surface 
from Gly-198 is encircled in orange (both according pgDPP4 numbering). (c) Crystal 
structure 2FJP [65] of hDPP4 showing compound S14 hydrogen bonded to Arg-358. Also 
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shown are Phe-357 and the potential stacking interaction with the phenyl ring of the S14 
ligand. 
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Figure 4: selectivity of the most potent compounds of the screening 
The pIC50 of hDPP (○) and DPP9 (●) is plotted versus the pIC50 of pgDPP4. Over an affinity 
range of more than two orders of magnitude, the IC50 of the inhibitors for DPP9 follow that of 
pgDPP4 whereas there is no corresponding increase in potency for hDPP4. Symbols above 
the diagonal (dotted line) indicate that the compound is more selective for the other enzyme 
than for pgDPP4. 
 
 
Figure 5: Optimal pharmacophore for pgDPP4. The features influencing the pgDPP4 
specificity over hDPP4 are circled in red. 
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